CHM-0201

CHM-0201 is an autologous chimeric antigen receptor (CAR) T-cell therapy that utilizes a chlorotoxin (CLTX)-based targeting domain. Chlorotoxin, a 36-amino acid peptide originally derived from scorpion venom, has been shown to bind specifically to glioblastoma cells via Matrix Metalloproteinase-2 (MMP2) and other components of the tumor surfaceome. By using CLTX instead of a traditional antibody-based single-chain variable fragment (scFv), CHM-0201 aims to achieve broader tumor recognition and reduced off-target effects, as MMP2 is highly expressed in glioblastoma and other solid tumors but has limited expression in healthy tissue. The therapy was originally developed at City of Hope and subsequently licensed by Chimeric Therapeutics for the treatment of recurrent or progressive glioblastoma and other MMP2-expressing solid tumors.

Other names

Chlorotoxin-based CAR TChlorotoxin-binding MMP2-CAR T cell therapy